FDA & Pipeline: FDA accepted an sNDA to extend the hormone-free MIUDELLA copper IUD from 3 to up to 6 years, and granted Priority Review to Takeda’s zasocitinib for moderate-to-severe plaque psoriasis. Oncology & Imaging: Telix’s TLX101-Px (Pixclara) won FDA approval for PET imaging in recurrent/progressive glioma, while AstraZeneca’s camizestrant plus palbociclib missed its PFS goal in first-line ER+/HER2– breast cancer. Dermatology: Biofrontera’s aminolevulinic acid topical gel (Ameluz) plus photodynamic therapy was approved for superficial basal cell carcinoma. Women’s Health & Stroke: A report highlights how estrogen, pregnancy, and reproductive history can shape stroke risk in women, and clinicians are urged to avoid reflexively labeling new neurologic symptoms as migraine. Safety Alerts: Centric Compounding recalled certain wellness injectables after elevated endotoxins were found. Access & Care Models: Saskatchewan expanded pharmacy services for strep throat and ear infections to 102 locations. Policy & Coverage: Minnesota will stop using hotel rooms for Medicaid-funded mental health crisis respite. Biotech/Business: Kite Pharma plans to relocate its home office in California, and Revolution Medicines earned Breakthrough Therapy Designation for RASONQUE in treatment-naïve metastatic pancreatic cancer.